Blackwhite wrote:This might seem like small news, but some more solid data for the immunotherapy checkpoint inhibitors has significance for two reasons: the FDA are approving this stuff on sight because of how well it can work, and pretty much for the first time a drug is being given based on shared defects across multiple tumours, rather than different drugs for particular kinds of tumour.
Eighteen out of 86 advanced cancer patients had their tumour disappear. Excellent stuff.
Edit: I hate this write up, but it might help explain it.
Obviously this will still be a good way off being mainstream treatment but how would an advanced/terminal cancer patient with numerous secondaries enquire about such an option? (And would there be much point).